UroGen Pharma (URGN) Cash Flow: Operating & Free Cash Flow

UroGen Pharma Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for UroGen Pharma Ltd. (URGN) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Operating Activities
Net Income	-153.49	-126.87	-102.24	-109.78	-110.82	-128.48	-105.15	-75.66	-20.00
Depreciation & Amortization	2.41	1.19	1.71	1.82	1.77	2.04	1.32	0.42	0.21
Deferred Income Tax	0.00	0.00	0.00	0.00	15.32	0.44	-0.57	0.00	0.00
Stock Based Compensation	11.96	13.11	9.34	10.58	23.11	28.03	29.97	30.64	6.30
Change in Working Capital	-27.91	4.93	3.34	-6.31	-13.11	-6.37	4.32	7.16	3.76
Change in Accounts Receivable	-12.78	-4.86	-2.74	-0.99	-4.67	-7.05	0.00	3.29	0.08
Change in Inventory	-7.24	-3.55	-1.35	-0.36	-2.87	-1.96	0.00	0.32	-0.21
Change in Accounts Payable	0.29	10.89	4.16	0.28	2.00	-1.25	2.93	4.21	2.53
Change in Other Working Capital	3.60	2.45	0.54	-5.24	-6.26	1.17	1.39	-0.65	1.35
Other Operating Activities	3.60	10.88	11.48	16.13	15.32	-1.54	-0.91	0.10	0.17
Net Cash from Operating Activities	-162.44	-96.77	-76.38	-87.56	-84.89	-105.89	-71.02	-37.33	-9.57
Investing Activities
Capital Expenditures	-0.29	-0.30	-0.19	-0.25	-0.75	-1.22	-0.33	-0.56	-0.27
Acquisitions	0.00	0.00	0.00	-1.31	-4.82	-94.45	0.00	0.00	0.00
Purchases of Investments	-77.40	-128.02	-49.83	-63.01	-51.90	94.45	-197.69	-0.05	-36.00
Sales/Maturities of Investments	139.25	107.71	49.07	64.32	56.72	124.14	52.59	35.90	0.00
Other Investing Activities	0.00	0.00	0.00	1.31	4.82	94.45	-0.17	-0.05	-0.11
Net Cash from Investing Activities	61.56	-20.61	-0.95	1.06	4.07	93.24	-145.59	35.29	-36.38
Financing Activities
Debt Repayment	-1.86	24.49	0.00	95.78	0.00	0.00	0.00	0.00	0.00
Common Stock Issued	39.80	151.17	116.93	1.35	0.06	16.59	161.66	64.24	60.84
Other Financing Activities	0.00	18.96	48.70	-0.16	-0.14	-0.07	3.59	2.19	0.74
Net Cash from Financing Activities	39.92	194.62	116.93	97.13	72.32	16.53	165.25	66.42	61.59
Summary
Net Change in Cash	-60.97	77.24	39.60	10.64	-8.50	3.88	-51.36	64.37	15.64
Cash at Beginning of Period	173.06	95.82	56.22	45.59	54.09	50.21	101.57	37.20	21.36
Cash at End of Period	112.10	173.06	95.82	56.22	45.59	54.09	50.21	101.57	37.00
Free Cash Flow	-162.73	-97.06	-76.57	-87.81	-85.64	-107.10	-71.34	-37.89	-9.84

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About UroGen Pharma Cash Flow

What is UroGen Pharma's free cash flow?

UroGen Pharma had negative free cash flow of $162.73M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$162.44M minus $289.00K of capital expenditures.

How much does UroGen Pharma spend on capital expenditures?

UroGen Pharma spent $289.00K on capital expenditures in fiscal 2025, compared with $295.00K a year earlier.

Does UroGen Pharma pay dividends or buy back shares?

UroGen Pharma's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition